Martínez-Gamboa David A, Kaner Justin
Division of Hematology and Medical Oncology, Mayo Clinic, Phoenix, AZ, USA.
Division of Hematology and Medical Oncology, Weill Cornell Medicine, New York, NY, USA.
Trends Cancer. 2025 Feb;11(2):81-83. doi: 10.1016/j.trecan.2025.01.006. Epub 2025 Jan 24.
The AUGMENT-101 clinical trial reported that the use of revumenib led to improved overall survival (OS) and complete remission (CR)/CR with partial hematologic recovery (CRh) in patients with acute leukemias and has released updated data with longer follow-up of Phase 2 results. Additionally, revumenib has received FDA approval for its use in relapsed or refractory (r/r) lysine methyltransferase 2A rearranged (KMT2A-r) acute leukemias.
AUGMENT-101临床试验报告称，使用瑞武尼布可改善急性白血病患者的总生存期（OS）以及完全缓解（CR）/伴有部分血液学恢复的完全缓解（CRh），并且已经公布了对2期结果进行更长时间随访的更新数据。此外，瑞武尼布已获得美国食品药品监督管理局（FDA）批准，用于复发或难治性（r/r）赖氨酸甲基转移酶2A重排（KMT2A-r）急性白血病。
